Published in Cancer on May 01, 2004
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer (2008) 1.24
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer (2011) 1.11
Local recurrence has only a small effect on survival in high-risk extremity osteosarcoma. Clin Orthop Relat Res (2011) 0.98
Role of surgical margin on local recurrence in high risk extremity osteosarcoma: a case-controlled study. Clin Orthop Surg (2013) 0.85
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. Ann Surg Oncol (2014) 0.81
The Variability in Surgical Margin Reporting in Limb Salvage Surgery for Sarcoma. Iowa Orthop J (2015) 0.80
Prevention of contamination by biopsy needle track contamination using a novel adriamycin-loaded gelatin sponge. World J Surg Oncol (2013) 0.80
The Current and Future Therapies for Human Osteosarcoma. Curr Cancer Ther Rev (2013) 0.79
What are the factors that affect survival and relapse after local recurrence of osteosarcoma? Clin Orthop Relat Res (2014) 0.79
CORR Insights(®): survival, recurrence, and function after epiphyseal preservation and allograft reconstruction in osteosarcoma of the knee. Clin Orthop Relat Res (2015) 0.75
Initial diagnostic management of pediatric bone tumors. J Pediatr Surg (2016) 0.75
Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002. Mol Ther Oncolytics (2017) 0.75
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 3.10
Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res (2007) 2.97
Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer (2007) 2.62
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol (2005) 2.41
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology (2011) 2.35
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol (2012) 2.32
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer (2007) 1.93
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol (2002) 1.82
Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.71
In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg (2007) 1.69
Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol (2011) 1.64
Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer (2002) 1.60
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.55
Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. J Infect Dis (2011) 1.49
Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol (2007) 1.46
Distinguishing benign from malignant pulmonary nodules with helical chest CT in children with malignant solid tumors. Radiology (2006) 1.42
Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Ther (2010) 1.34
Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer (2010) 1.33
Survival of pediatric patients after relapsed osteosarcoma: the St. Jude Children's Research Hospital experience. Cancer (2013) 1.32
Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol (2003) 1.32
Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer (2008) 1.30
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer (2004) 1.29
Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology (2008) 1.28
Metastatic osteosarcoma. Cancer (2006) 1.27
Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res (2004) 1.26
PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease. AJR Am J Roentgenol (2006) 1.26
Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer (2008) 1.25
Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer (2008) 1.24
Disease control intervals in high-risk neuroblastoma. Cancer (2008) 1.20
Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol (2004) 1.18
Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer (2013) 1.16
Early multicenter experience with a noninvasive expandable prosthesis. Clin Orthop Relat Res (2003) 1.15
Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer (2004) 1.14
Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.14
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13
Epigenetic modulation of Homer1a transcription regulation in amygdala and hippocampus with pavlovian fear conditioning. J Neurosci (2012) 1.12
Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer (2011) 1.11
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. Cancer (2011) 1.11
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. J Clin Oncol (2014) 1.09
Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. Cancer (2005) 1.08
Continuous delivery of IFN-beta promotes sustained maturation of intratumoral vasculature. Mol Cancer Res (2007) 1.07
Height at diagnosis and birth-weight as risk factors for osteosarcoma. Cancer Causes Control (2011) 1.07
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res (2012) 1.06
Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs (2007) 1.06
A comparative analysis of functional outcomes in adolescents and young adults with lower-extremity bone sarcoma. Pediatr Blood Cancer (2007) 1.05
Infections in children and young adults with bone malignancies undergoing limb-sparing surgery. Cancer (2005) 1.04
Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2012) 1.03
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer (2012) 1.02
Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer (2008) 0.99
Late effects of pelvic rhabdomyosarcoma and its treatment in female survivors. J Clin Oncol (2005) 0.99
Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol (2006) 0.98
Initial testing (stage 1) of LCL161, a SMAC mimetic, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 0.98
Clinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcoma. J Clin Oncol (2002) 0.97
Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer (2009) 0.95
Ewing sarcoma-family tumors that arise after treatment of primary childhood cancer. Cancer (2006) 0.95
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol (2007) 0.95
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol (2009) 0.94
Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol (2006) 0.94
Clinical management of infantile fibrosarcoma: a retrospective single-institution review. Pediatr Surg Int (2013) 0.94
ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS One (2008) 0.94
Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma. Pediatr Blood Cancer (2012) 0.93
Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature. J Pediatr Surg (2003) 0.93
Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience. Ann Surg Oncol (2012) 0.93
Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.93
The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. Br J Haematol (2008) 0.93
Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer (2003) 0.93
Malignant fibrous histiocytoma and other fibrohistiocytic tumors in pediatric patients: the St. Jude Children's Research Hospital experience. Cancer (2003) 0.92